Finland · Delayed Price · Currency is EUR Revenio Group Oyj Earnings Call Transcripts
Fiscal Year 2026
-
Q1 saw 8.4% FX-adjusted sales growth, strong U.S. and Europe performance, but lower operating profit due to Visionix transaction costs. The Visionix acquisition expands the addressable market and product portfolio, with significant synergies and a rights issue planned for H2.
-
The merger creates a leading ophthalmic diagnostics company with a EUR 2.5 billion accessible market, targeting EUR 20 million in synergies and 25% EBITDA margin by 2028-2029. Integration is structured for rapid synergy capture, with strong shareholder and leadership commitment.
Fiscal Year 2025
-
Q4 and full-year 2025 saw strong sales growth, record US performance, and robust cash flow, despite margin pressure from tariffs and delayed price increases. 2026 guidance anticipates 8%-15% sales growth, with profitability supported by ongoing price adjustments and a strong product pipeline.
-
Q3 delivered 8.1% sales growth and 9.1% higher operating profit, led by strong European and U.S. performance in screening devices and software. Guidance remains unchanged, with Q4 expected to be the strongest quarter. New product launches and robust financials support a positive outlook.
-
Q2 saw 4.2% reported sales growth (7.2% currency-adjusted), with all regions and product categories contributing. Gross margin exceeded 70%, and adjusted operating profit rose ~10% in Q2. Tariff impacts are being managed with planned price increases as inventory runs out.
-
Q1 2025 saw strong organic growth across all regions and product lines, with net sales up 10.5% and EBIT margin at 25.4%. U.S. tariffs and FX volatility pose risks, but price increases and natural hedging are in place. Guidance targets 6%-15% sales growth and stable profitability.
Fiscal Year 2024
-
Q4 and full-year 2024 saw strong sales growth, robust profitability, and record cash flow, driven by new product launches and recurring revenue. Guidance for 2025 anticipates 6%-15% sales growth, with profitability remaining strong despite geopolitical and regulatory risks.
-
Q3 saw 8.9% net sales growth (15.1% FX-adjusted), strong product launches, and robust performance in imaging and tonometer segments. FX headwinds and higher marketing costs impacted margins, but full-year sales are expected to surpass EUR 100 million.
-
Q2 net sales grew 14.2% year-over-year, driven by strong performance in fundus imaging and tonometers, with stable margins and robust cash flow. Guidance for 2024 remains at 5%-10% net sales growth, with profitability expected to stay strong. Clinical trial costs and an off-balance sheet contingent liability are key uncertainties.